CANDOR 研究中复发/难治性多发性骨髓瘤患者基于细胞遗传学风险的亚组分析。
Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study.
机构信息
Division of Hematology, Sylvester Comprehensive Cancer Center, Miami, Florida, USA.
Department of Oncology, Hematology and BMT, University Medical Center of Hamburg-Eppendorf, Hamburg, Germany.
出版信息
Br J Haematol. 2022 Sep;198(6):988-993. doi: 10.1111/bjh.18233. Epub 2022 May 24.
CANDOR compared the safety/efficacy of carfilzomib with dexamethasone and daratumumab (KdD) to carfilzomib with dexamethasone (Kd) in adults with relapsed/refractory multiple myeloma (RRMM). This CANDOR subgroup analysis evaluated outcomes based on cytogenetic risk. Overall response rates (KdD vs. Kd) were 81% versus 56% in high-risk and 87% versus 79% in standard-risk groups. Median progression-free survival was 11.2 versus 7.4 months in high-risk (hazard ratio, 0.56 [95% CI, 0.34, 0.93]) and not reached versus 16.6 months in standard-risk groups (0.56 [95% CI, 0.39, 0.80]). These data support the efficacy of KdD in RRMM treatment, including in patients with high-risk cytogenetics.
CANDOR 研究比较了卡非佐米联合地塞米松和达雷妥尤单抗（KdD）与卡非佐米联合地塞米松（Kd）治疗复发/难治性多发性骨髓瘤（RRMM）成人患者的安全性/疗效。本 CANDOR 亚组分析根据细胞遗传学风险评估了结局。高危组的总缓解率（KdD 对比 Kd）分别为 81%对比 56%，标准风险组分别为 87%对比 79%。高危组的中位无进展生存期为 11.2 个月对比 7.4 个月（危险比，0.56 [95% CI，0.34，0.93]），标准风险组未达到 16.6 个月（0.56 [95% CI，0.39，0.80]）。这些数据支持 KdD 在 RRMM 治疗中的疗效，包括在细胞遗传学高危的患者中。
Zotero 插件